PharmaJet Announces Addition of Melissa Malhame as VP Business Development
Brings extensive experience in vaccine development and sales to the leadership team
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet®, the maker of innovative, needle-free injection technology, today announced that Melissa Malhame, has joined the leadership team as Vice President, Business Development. Ms. Malhame is a global business executive with over 25 years of experience in business development, strategic sales, and marketing for major vaccine providers such as Gavi, Dynavax and Merck, as well as supporting global health investments in new vaccine candidates and expanding access to existing vaccines. In this role she will be leading business development, sales, and marketing for the Pharmajet organization.
Chris Cappello, President and CEO, PharmaJet Inc., said, “We are very pleased to welcome Ms. Malhame to the PharmaJet leadership team. Her strategic business development expertise with major vaccine companies, as well as her extensive experience with Gavi and other key global health organizations will help drive the expansion and use of our Needle-free injection system technology.”
Since 1994 Ms. Malhame held key business development and sales roles at prominent vaccine companies and funding organizations. As head of Market Shaping at Gavi, The Vaccine Alliance, she managed $1 billion of annual vaccine funding. In that role, she established strategies for 10 vaccine markets and cold chain equipment, created and executed a unique business strategy for the Ebola vaccine, and built and maintained relationships with the WHO, UNICEF and The Bill and Melinda Gates Foundation. Prior to joining Gavi, she held business development, strategic marketing and sales roles at Merck & Company and Dynavax Technologies, supporting the vaccine and respiratory categories, as well as vaccine candidates including Heplisav-B®. Ms. Malhame holds an MBA from Cornell University and a Bachelor of Arts degree in Economics & International Affairs from Lafayette College.
Ms. Malhame added, “I am delighted to be joining the PharmaJet organization and look forward to bringing my skills and expertise to an already talented leadership team, expanding the use of the PharmaJet technology globally.”
For more information about PharmaJet visit www.pharmajet.com.
PharmaJet’s mission is worldwide acceptance of PharmaJet Needle-free Injection Systems as a standard of care in the vaccine delivery market. The PharmaJet Needle-free Systems are safe, fast and easy-to-use. They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit www.pharmajet.com.
1-888-900-4321 Option 3